Replies to post #62 on Context Therapeutics Inc (CNTX)

[Hercules1]

$CNTX:

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU(TM) (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
7:30 am ET January 31, 2023 (Globe Newswire) Print
GlobeNewswireJanuary 31, 2023


First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer

[stokbrokin]

Hey thats my old company I worked with!! Lenox Gltua peace stok